Levodopa Concentration Profile With Stalevo 75/125 mg
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm that the dose levels and dosing frequency utilising
the new Stalevo strengths would result into more stable levodopa plasma levels. Therefore, it
is anticipated that when lower dose of Stalevo is administered after the first higher dose of
Stalevo, this would result in equally high levodopa maximum concentration values (Cmax) after
each dose throughout the day compared to Cmax after the first dose.
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Carbidopa Carbidopa, levodopa drug combination Entacapone Levodopa